Follow-up of patients with severe eosinophilic asthma receiving mepolizumab for one year in specialized asthma clinics in Greece
作者
Maria Kallieri,Εleftherios Ζervas,Κonstantinos Κatsoulis,Evangelia Fouka,Κonstantinos Porpodis,Κonstantinos Samitas,Andriana Papaioannou,Maria Kipourou,Panagiotis Lyberopoulos,Εleni Gaki,Stylianos K. Vittorakis,Μiltiadis Μarkatos,Katerina Dimakou,Sevasti Ampelioti,Sofia Koukidou,Michail Makris,Maria Ntakoula,Marija Hadji-Mitrova,Spyridon A. Papiris,Νikolaos Tzanakis
标识
DOI:10.1183/13993003.congress-2020.1414
摘要
Introduction: Μepolizumab is a monoclonal antibody against IL-5 for the treatment of severe eosinophilic asthma. The aim of the current study was to present a predesigned interim analysis of the data of patients who have completed one year of therapy with mepolizumab. Material and Method: This study is a prospective multi-centre, non-interventional 2 -year observational study and aims to describe the clinical benefit and safety profile of mepolizumab in patients with severe eosinophilic asthma. Results: Compared to the year preceding the initiation of treatment, the annual rate of exacerbations decreased significantly, from 4.3±2.3 to 1.3±1.8; p <0.0001. 42 patients received maintenance dose of OCS at baseline. From these patients at the end of one year of therapy with mepolizumab 17 patients (40%) had achieved OCS discontinuation. A reduction in the median dose of OCS was also achieved. After 1 year of treatment with mepolizumab the ACT score significantly increased from 16.3±3.7 to 21.2±3.8 (p<0.0001). This marked clinical improvement was paralleled by a significant reduction of blood eosinophil count. All patients showed a considerable improvement of airflow limitation. In respect to Adverse Events (AE) of treatment with mepolizumab, 19 patients (27%) were recorded to have at least one such occurrence during their 1-year treatment. Conclusions: We have shown that in patients with severe eosinophilic asthma, one year of treatment with mepolizumab was safe, resulted in significant reduction of the annual exacerbation rate, reduction (or even discontinuation) of the needed dose of oral corticosteroids, and improvements of asthma control and lung function.